Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
resistant starch
- Development stage
- Phase 3
- Lead developer
- Yale University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Resistant starch is a dietary supplement intervention, specifically resistant potato starch, being evaluated by Yale University for the treatment of non-hospitalized COVID-19 patients. The biological mechanism involves the fermentation of the starch by gut microbiota into short-chain fatty acids, primarily butyrate. Butyrate is hypothesized to act as an anti-inflammatory agent by suppressing the production of pro-inflammatory cytokines, most notably interleukin-6 (IL-6), which is often elevated in severe COVID-19 cases. By modulating the systemic inflammatory response, the intervention aims to reduce hospitalization rates and accelerate clinical recovery. This nutritional approach was studied in a Phase 2/3 randomized, quadruple-blinded clinical trial (NCT04342689) involving collaborators from the University of Michigan and the University of Minnesota.
- Other names
- resistant potato starchbutyrate-producing dietary supplement
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on resistant starch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on resistant starch.